Babson Capital Corporate Investors(MCI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MCI Babson Capital Corporate Investors

Market Closed 03-27 16:00:00 EDT

17.61

-0.90

-4.86%

盘后17.61

+0.000.00%

16:10 EDT

High18.78	Low17.50	Vol94.65K
Open18.54	D1 Closing18.51	Amplitude6.89%
Mkt Cap360.98M	Tradable Cap0.00	Total Shares20.50M
T/O1.69M	T/O Rate--	Tradable Shares0.00
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MCI","market":"US","secType":"STK","nameCN":"Babson Capital Corporate Investors","latestPrice":17.61,"timestamp":1774641600000,"preClose":18.51,"halted":0,"volume":94653,"hourTrading":{"tag":"盘后","latestPrice":17.61,"preClose":17.61,"latestTime":"16:10 EDT","volume":10,"amount":176.1,"timestamp":1774642204884,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.04862236628849282,"floatShares":0,"shares":20498532,"eps":1.367024,"marketStatus":"Market Closed","change":-0.9,"latestTime":"03-27 16:00:00 EDT","open":18.54,"high":18.775,"low":17.5,"amount":1692780.322951,"amplitude":0.068882,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.367024,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":18.51,"dividendRate":0.090818,"postHourTrading":{"tag":"盘后","latestPrice":17.61,"preClose":17.61,"latestTime":"16:10 EDT","volume":10,"amount":176.1,"timestamp":1774642204884,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":4.274547},"requestUrl":"/m/hq/s/MCI/tweets","defaultTab":"tweets","newsList":[{"id":"2622854655","title":"Press Release: Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2622854655","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622854655?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:30","pubTimestamp":1774524600,"startTime":"0","endTime":"0","summary":"- Meeting with FDA Division of Psychiatry expected by mid-2026 -. \"Our progress in 2025 and early 2026 has culminated in a clinical development plan to advance zervimesine for the treatment of psychosis associated with DLB. This patient population has no approved options today and has demonstrated their support of zervimesine's advancement to registrational trials,\" said Lisa Ricciardi, Cognition's president and CEO. \"We received valuable feedback from regulators on both our DLB and Alzheimer's programs. Our 545-patient 'START' trial in early Alzheimer's disease has completed enrollment. Upon reviewing the results in 2027, we will determine how to advance zervimesine in Alzheimer's disease. With our near-term focus on DLB, our next steps are centered on a meeting with the FDA Division of Psychiatry to seek alignment on our registrational plan for zervimesine for the treatment of DLB psychosis.\"","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0240878834.USD","CGTX","LU0345774631.USD","MCI","DLB","BK4007","LU0348723411.USD","LU0205193047.USD","LU0240877869.USD","BK4097","LU0345774391.USD","LU0205194284.USD"],"gpt_icon":0},{"id":"2622004796","title":"Barings Corporate Investors announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2622004796","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622004796?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:17","pubTimestamp":1774469846,"startTime":"0","endTime":"0","summary":"Barings Corporate Investors will hold its annual shareholder meeting virtually on May 14, 2026.Shareholders will vote on the election of trustees Michael H. Brown, Barbara M. Ginader and Maleyne M. Syracuse.Other business may be considered if properly brought before the meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Barings Corporate Investors published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 25, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL36PpW9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MCI"],"gpt_icon":0},{"id":"2621261758","title":"Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2621261758","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621261758?lang=en_us&edition=fundamental","pubTime":"2026-03-21 00:05","pubTimestamp":1774022700,"startTime":"0","endTime":"0","summary":"Real-World LEQEMBI Data Shows Patients Choose to Stay on Long-Term TreatmentTOKYO and CAMBRIDGE, Mass., March  20, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eis","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/20/3259865/0/en/Results-from-Real-World-Long-Term-Treatment-Persistence-with-LEQEMBI-lecanemab-irmb-in-the-United-States-Presented-at-AD-PD-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","LU1169589451.USD","BK4023","AD","PD","CDR","BK4211","UBCP","CSF","LU1169590202.USD","BK4132","MCI"],"gpt_icon":0},{"id":"2620335261","title":"Noreen Clifford, Chairman of Fund, disposed of USD 188,000 in Barings Corporate Investors common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2620335261","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620335261?lang=en_us&edition=fundamental","pubTime":"2026-03-19 03:08","pubTimestamp":1773860908,"startTime":"0","endTime":"0","summary":"Noreen Clifford, chairman of the fund and a director and officer of Barings Corporate Investors, reported beneficial ownership of 20,000 common shares. The filing also reported a transaction on March 17, 2026 involving 9,662.75 shares under the Barings Non-Qualified Thrift Plan at a price of USD 19.53. Following the reported transaction, plan-related holdings were reported at 309,207.87 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Barings Corporate Investors published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL5qzZ07:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Noreen Clifford, Chairman of Fund, disposed of USD 188,000 in Barings Corporate Investors common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MCI"],"gpt_icon":0},{"id":"2616884618","title":"Barings Corporate Investors Publishes 2025 Annual Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2616884618","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616884618?lang=en_us&edition=fundamental","pubTime":"2026-03-01 04:03","pubTimestamp":1772309032,"startTime":"0","endTime":"0","summary":"Barings Corporate Investors published its 2025 annual report, outlining results for the year ended December 31, 2025. The report says the Trust’s investment objective remains focused on generating current yield with opportunities for capital gains, primarily through privately placed below-investment-grade long-term debt, including bank loans and mezzanine instruments, sometimes with equity features. Barings Corporate Investors reported positive net total portfolio return for 2025 based on net asset value and dividend reinvestment, while its share price declined over the same period. The report also describes continued portfolio activity during 2025, including new investments and add-on investments, with investment activity supported by refinancings and additional funding to existing portfolio companies. The full report can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to pr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260228:nNDL6L44md:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MCI"],"gpt_icon":0},{"id":"2614794610","title":"Barings Corporate Investors Q4 net unrealized appreciation at USD 986,805.0 million after Q3 net unrealized depreciation of USD 419,454.0 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614794610","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614794610?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:29","pubTimestamp":1772141379,"startTime":"0","endTime":"0","summary":"Barings Corporate Investors Q4 net unrealized appreciation at USD 986,805.0 million after Q3 net unrealized depreciation of USD 419,454.0 million. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Barings Corporate Investors published the original content used to generate this news brief on February 26, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL680ct6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MCI"],"gpt_icon":0},{"id":"2614076403","title":"Barings Corporate Investors Q4 Dividend USD 0.4","url":"https://stock-news.laohu8.com/highlight/detail?id=2614076403","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614076403?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:15","pubTimestamp":1772140502,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nPLX169684:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MCI"],"gpt_icon":0},{"id":"2614767510","title":"Press Release: Barings Corporate Investors Reports Preliminary Fourth Quarter 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2614767510","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614767510?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:15","pubTimestamp":1772140500,"startTime":"0","endTime":"0","summary":"The Board of Trustees of Barings Corporate Investors   met on February 26, 2026, and would like to report its preliminary financial results for the fourth quarter of 2025.   December 31, 2025 figures net of approximately $0.03 per share of excise.    December 31, 2025 figures net of approximately $0.01 per share of.    Based on shares outstanding at the end of the period of 20,498,532.    Based on shares outstanding at the end of the period of 20,525,807. In 2025, The Trust maintained its quarterly dividend at $0.40 per share, which is further confirmation of our credit philosophy, where we focus on leading businesses backed by strong sponsor ownership and conservative capital structures. This resulted in a total annual dividend of $1.60 per share. Based on the Trust's December 31, 2025, share price of $18.15 per share, the most recent regular quarterly distribution of $0.40 per share represents an annualized yield of 8.8%.During the three months ended December 31, 2025, the Trust repo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","ISBC","MCI"],"gpt_icon":0},{"id":"2590788546","title":"Barings Corporate Investors announces $0.40 per share quarterly dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2590788546","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590788546?lang=en_us&edition=fundamental","pubTime":"2025-12-12 04:30","pubTimestamp":1765485013,"startTime":"0","endTime":"0","summary":"Barings Corporate Investors  has announced a quarterly dividend of $0.40 per share, payable on January 16, 2026, to shareholders of record on December 30, 2025. The dividend amount is based on current projections through the end of 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Barings Corporate Investors published the original content used to generate this news brief via Business Wire  on December 11, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL41R1rp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MCI"],"gpt_icon":0},{"id":"2588302060","title":"Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2588302060","media":"GlobeNewswire","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588302060?lang=en_us&edition=fundamental","pubTime":"2025-12-04 07:10","pubTimestamp":1764803400,"startTime":"0","endTime":"0","summary":"Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate Alzheimer’s disease by up to 8.3 years in low-amyloid group who started tre","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/03/3199431/0/en/Eisai-Presents-New-Data-on-the-Continued-and-Expanding-Benefit-of-LEQEMBI-lecanemab-irmb-Maintenance-Treatment-in-Early-Alzheimer-s-Disease-at-the-Clinical-Trials-on-Alzheimer-s-Di.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARIA","CAA","MCI","AD","BK4132"],"gpt_icon":0},{"id":"2588186061","title":"New Data Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF","url":"https://stock-news.laohu8.com/highlight/detail?id=2588186061","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588186061?lang=en_us&edition=fundamental","pubTime":"2025-12-03 05:40","pubTimestamp":1764711600,"startTime":"0","endTime":"0","summary":"TOKYO and CAMBRIDGE, Mass., Dec.  02, 2025  (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/02/3198449/0/en/New-Data-Presented-at-the-Clinical-Trials-on-Alzheimer-s-Disease-CTAD-Conference-2025-Confirms-Pharmacological-Effect-of-LEQEMBI-lecanemab-irmb-on-Neurotoxic-A%CE%B2-Protofibrils-in-CSF.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAA","BK4132","AD","MCI","ARIA","CSF"],"gpt_icon":0},{"id":"2586279939","title":"Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2586279939","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586279939?lang=en_us&edition=fundamental","pubTime":"2025-11-28 08:30","pubTimestamp":1764289800,"startTime":"0","endTime":"0","summary":"If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the initiation of treatment for this progressive, relentless diseaseTOKYO and CAMB","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/28/3195968/0/en/Eisai-Submits-New-Drug-Application-for-Subcutaneous-Formulation-of-LEQEMBI-for-the-Treatment-of-Early-Alzheimer-s-Disease-in-Japan.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MCI","BK4132","AD"],"gpt_icon":0},{"id":"2586478988","title":"Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status","url":"https://stock-news.laohu8.com/highlight/detail?id=2586478988","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586478988?lang=en_us&edition=fundamental","pubTime":"2025-11-25 20:30","pubTimestamp":1764073800,"startTime":"0","endTime":"0","summary":"LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start of therapy to help patients and care partners treat this ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/25/3194237/0/en/Eisai-Completes-Rolling-Submission-to-US-FDA-for-LEQEMBI-IQLIK-lecanemab-irmb-Supplemental-Biologics-License-Application-as-a-Subcutaneous-Starting-Dose-for-the-Treatment-of-Early-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MCI","CAA","IE00B5TLWC47.USD","BK4567","FAST","IE00BYQQ9H92.USD","IE00BFXG0V08.USD","BK4104","BK4132","ARIA","BK4585","BK4588","AD"],"gpt_icon":0},{"id":"2583454536","title":"“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom","url":"https://stock-news.laohu8.com/highlight/detail?id=2583454536","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583454536?lang=en_us&edition=fundamental","pubTime":"2025-11-14 07:30","pubTimestamp":1763076600,"startTime":"0","endTime":"0","summary":"TOKYO and CAMBRIDGE, Mass., Nov.  13, 2025  (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massa","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/13/3187962/0/en/LEQEMBI-lecanemab-IV-Maintenance-Dosing-for-the-Treatment-of-Early-Alzheimer-s-Disease-Approved-in-the-United-Kingdom.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UBCP","BK4211","BK4132","AAIC","AD","MCI","BK4110"],"gpt_icon":0},{"id":"2583519622","title":"Barings Corporate Investors reports Q3 net investment income of $7.1 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583519622","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583519622?lang=en_us&edition=fundamental","pubTime":"2025-11-14 04:30","pubTimestamp":1763065825,"startTime":"0","endTime":"0","summary":"Barings Corporate Investors reported preliminary third quarter 2025 results with total investment income of $9.2 million. Net investment income for the quarter was $7.1 million, or $0.35 per share, consistent with the previous quarter. Net realized gains were $0.6 million, or $0.03 per share, while net unrealized depreciation was $0.4 million, or $0.02 per share. The net increase in net assets resulting from operations was $7.2 million, or $0.35 per share, compared to $8.8 million, or $0.43 per share, in the prior quarter. Total net assets at September 30, 2025, were $349.6 million. During the quarter, the Trust made 13 new investments totaling $15.5 million and 41 add-on investments in existing portfolio companies totaling $15.3 million. As of quarter end, the Trust held $14.4 million in cash, $43.5 million in borrowings, and had unfunded commitments of $41.9 million. The Trust maintained its dividend for the quarter.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL7P2FPg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MCI"],"gpt_icon":0},{"id":"2581787077","title":"Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer’s Disease and Dementia","url":"https://stock-news.laohu8.com/highlight/detail?id=2581787077","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581787077?lang=en_us&edition=fundamental","pubTime":"2025-11-05 21:30","pubTimestamp":1762349400,"startTime":"0","endTime":"0","summary":"This strategic filing with the FDA follows encouraging internal data and recent published studies supporting Nexalin’s frequency neurostimulator as a potential non-invasive therapy for cognitive disor","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/05/3181482/0/en/Nexalin-Technology-s-Q-Submission-for-Gen-2-SYNC-Accepted-by-U-S-FDA-for-the-Treatment-of-Alzheimer-s-Disease-and-Dementia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDE","BK4585","LU2286300806.USD","GEN","BK4588","MCI","BK4097"],"gpt_icon":0},{"id":"2575267577","title":"India Inflation Cools Further in September","url":"https://stock-news.laohu8.com/highlight/detail?id=2575267577","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575267577?lang=en_us&edition=fundamental","pubTime":"2025-10-14 16:52","pubTimestamp":1760431930,"startTime":"0","endTime":"0","summary":"India retail inflation rate struck an eight-year low in September, while wholesale prices were nearly unchanged on year, reported New Delhi on TuesdayIndia's headline consumer price index (CPI) rose a","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MNDmain","BK4213","CPI","GDP","MCI"],"gpt_icon":0},{"id":"2575589231","title":"LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”","url":"https://stock-news.laohu8.com/highlight/detail?id=2575589231","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575589231?lang=en_us&edition=fundamental","pubTime":"2025-10-14 07:30","pubTimestamp":1760398200,"startTime":"0","endTime":"0","summary":"TOKYO and CAMBRIDGE, Mass., Oct.  13, 2025  (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/13/3165850/0/en/LEQEMBI-IQLIK-lecanemab-irmb-Subcutaneous-Autoinjector-Named-to-TIME-s-Best-Inventions-of-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TIME","ARIA","BK4132","CAA","AD","MCI"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.barings.com","stockEarnings":[{"period":"1week","weight":-0.0876},{"period":"1month","weight":-0.1456},{"period":"3month","weight":-0.1024},{"period":"6month","weight":-0.1505},{"period":"1year","weight":-0.21},{"period":"ytd","weight":-0.0298}],"compareEarnings":[{"period":"1week","weight":-0.0223},{"period":"1month","weight":-0.0852},{"period":"3month","weight":-0.0814},{"period":"6month","weight":-0.0419},{"period":"1year","weight":0.1182},{"period":"ytd","weight":-0.0701}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Babson Capital Corporate Investors trust is a closed ended fixed income mutual fund launched and managed by Barings LLC. It invests in fixed income markets of the United States. The fund seeks to invest in securities of companies operating across diversified sectors. It primarily invests in a portfolio of privately placed, below-investment grade, long term corporate debt obligations. The fund also invests in marketable investment grade debt securities, other marketable debt securities, and marketable common stocks. It was formerly known as Babson Capital Corporate Investors. Babson Capital Corporate Investors trust was formed in 1971 and is domiciled in the United States.","yearOnYearQuotes":[{"month":1,"riseRate":0.652174,"avgChangeRate":0.024832},{"month":2,"riseRate":0.586957,"avgChangeRate":0.009711},{"month":3,"riseRate":0.369565,"avgChangeRate":-0.021559},{"month":4,"riseRate":0.521739,"avgChangeRate":0.005381},{"month":5,"riseRate":0.673913,"avgChangeRate":0.025865},{"month":6,"riseRate":0.434783,"avgChangeRate":-0.009196},{"month":7,"riseRate":0.673913,"avgChangeRate":0.005815},{"month":8,"riseRate":0.586957,"avgChangeRate":0.010635},{"month":9,"riseRate":0.586957,"avgChangeRate":-0.00409},{"month":10,"riseRate":0.543478,"avgChangeRate":-0.004764},{"month":11,"riseRate":0.652174,"avgChangeRate":0.021016},{"month":12,"riseRate":0.369565,"avgChangeRate":-0.011097}],"exchange":"NYSE","name":"Babson Capital Corporate Investors","nameEN":"Babson Capital Corporate Investors"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Babson Capital Corporate Investors(MCI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Babson Capital Corporate Investors(MCI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Babson Capital Corporate Investors,MCI,Babson Capital Corporate Investors股票,Babson Capital Corporate Investors股票老虎,Babson Capital Corporate Investors股票老虎国际,Babson Capital Corporate Investors行情,Babson Capital Corporate Investors股票行情,Babson Capital Corporate Investors股价,Babson Capital Corporate Investors股市,Babson Capital Corporate Investors股票价格,Babson Capital Corporate Investors股票交易,Babson Capital Corporate Investors股票购买,Babson Capital Corporate Investors股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Babson Capital Corporate Investors(MCI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Babson Capital Corporate Investors(MCI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction